Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHE NYSEMKT:IGC NASDAQ:ITRM NYSEAMERICAN:MTNB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.50+4.4%$4.79$1.00▼$7.00$38.22M0.318,164 shs4.24 million shsIGCIGC Pharma$0.42+27.6%$0.40$0.25▼$0.48$37.97M1.04913,992 shs214,616 shsITRMIterum Therapeutics$0.81+5.6%$0.72$0.61▼$3.02$36.08M3.24778,516 shs1.36 million shsMTNBMatinas Biopharma$1.86-0.5%$1.72$0.47▼$4.25$9.51M1.4358,104 shs33,060 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics+4.41%+7.40%-10.36%-1.96%+243.51%IGCIGC Pharma-0.72%+3.48%-0.72%+9.47%+12.74%ITRMIterum Therapeutics+5.65%+20.65%+15.26%-28.50%-11.20%MTNBMatinas Biopharma-0.53%-3.63%+13.41%+80.58%+901.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.50+4.4%$4.79$1.00▼$7.00$38.22M0.318,164 shs4.24 million shsIGCIGC Pharma$0.42+27.6%$0.40$0.25▼$0.48$37.97M1.04913,992 shs214,616 shsITRMIterum Therapeutics$0.81+5.6%$0.72$0.61▼$3.02$36.08M3.24778,516 shs1.36 million shsMTNBMatinas Biopharma$1.86-0.5%$1.72$0.47▼$4.25$9.51M1.4358,104 shs33,060 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics+4.41%+7.40%-10.36%-1.96%+243.51%IGCIGC Pharma-0.72%+3.48%-0.72%+9.47%+12.74%ITRMIterum Therapeutics+5.65%+20.65%+15.26%-28.50%-11.20%MTNBMatinas Biopharma-0.53%-3.63%+13.41%+80.58%+901.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHEAlterity Therapeutics 2.00Hold$12.00166.67% UpsideIGCIGC Pharma 3.00Buy$3.88831.49% UpsideITRMIterum Therapeutics 2.00Hold$9.001,013.86% UpsideMTNBMatinas Biopharma 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest MTNB, ATHE, IGC, and ITRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ATHEAlterity TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ITRMIterum TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ATHEAlterity TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ITRMIterum TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHEAlterity TherapeuticsN/AN/AN/AN/A$3.10 per shareN/AIGCIGC Pharma$1.33M28.83N/AN/A$0.08 per share5.20ITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/AMTNBMatinas Biopharma$1.10M8.61N/AN/A$1.49 per share1.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHEAlterity Therapeutics-$7.87MN/A0.00∞N/AN/AN/AN/AN/AIGCIGC Pharma-$13M-$0.07N/AN/AN/A-714.16%-122.44%-88.40%N/AITRMIterum Therapeutics-$24.77M-$0.85N/A∞N/AN/AN/A-65.01%11/13/2025 (Estimated)MTNBMatinas Biopharma-$24.25M-$3.89N/A∞N/AN/A-210.21%-138.39%N/ALatest MTNB, ATHE, IGC, and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ITRMIterum Therapeutics-$0.13-$0.16-$0.03-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHEAlterity TherapeuticsN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AMTNBMatinas BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHEAlterity TherapeuticsN/A12.9812.98IGCIGC Pharma0.021.150.98ITRMIterum TherapeuticsN/A2.692.52MTNBMatinas BiopharmaN/A4.074.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHEAlterity Therapeutics2.14%IGCIGC Pharma3.87%ITRMIterum Therapeutics9.21%MTNBMatinas Biopharma11.77%Insider OwnershipCompanyInsider OwnershipATHEAlterity Therapeutics38.80%IGCIGC Pharma23.66%ITRMIterum Therapeutics2.40%MTNBMatinas Biopharma4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableIGCIGC Pharma6191.96 million54.60 millionN/AITRMIterum Therapeutics1047.17 million46.04 millionNot OptionableMTNBMatinas Biopharma305.09 million4.85 millionN/AMTNB, ATHE, IGC, and ITRM HeadlinesRecent News About These CompaniesMatinas Biopharma (NYSE:MTNB) Trading 3.2% Higher - Here's What HappenedOctober 3, 2025 | americanbankingnews.comMatinas BioPharma Holdings, Inc. (MTNB) Restructures Amid Challenges, Focuses on Oral Antifungal MAT2203September 24, 2025 | msn.comMTNB Matinas BioPharma Holdings, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comMatinas BioPharma Holdings, Inc. (MTNB) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comKalkine Matinas BioPharma Surges Amid NYSE Composite Market MomentumJune 7, 2025 | kalkinemedia.comKMatinas BioPharma amends bylaws, updates on officer agreementsMay 4, 2025 | investing.comMatinas BioPharma files to sell 16.9M shares of common stock for holdersApril 24, 2025 | markets.businessinsider.comMatinas BioPharma secures shareholder nods on key proposalsApril 6, 2025 | investing.comMatinas BioPharma announces board chairman’s departureMarch 16, 2025 | investing.comMatinas BioPharma appoints Murphy, Neugeboren to board of directorsMarch 11, 2025 | markets.businessinsider.comMatinas BioPharma Appoints Seasoned Biotech Leaders to Board of DirectorsMarch 11, 2025 | finance.yahoo.comMatinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of DirectorsFebruary 13, 2025 | globenewswire.comMatinas BioPharma announces board member retirementFebruary 11, 2025 | msn.comMatinas BioPharma Appoints Evelyn D’An as Independent Director and Audit Committee ChairFebruary 9, 2025 | nasdaq.comMatinas BioPharma appoints Evelyn D’An to board of directorsFebruary 7, 2025 | markets.businessinsider.comMatinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee ChairFebruary 7, 2025 | finance.yahoo.comMatinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee ChairFebruary 7, 2025 | globenewswire.comMatinas BioPharma announces board member resignationJanuary 25, 2025 | msn.com111 Equity Group increases stake in Matinas BioPharmaJanuary 24, 2025 | markets.businessinsider.com111 Equity ups stake in Matinas Biopharma HoldingsJanuary 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Not Just NVDA: 3 Semiconductor Stocks Struggling This QuarterBy Dan Schmidt | September 12, 2025MTNB, ATHE, IGC, and ITRM Company DescriptionsAlterity Therapeutics NASDAQ:ATHE$4.50 +0.19 (+4.41%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$4.10 -0.40 (-8.93%) As of 05:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.IGC Pharma NYSEMKT:IGC$0.42 +0.09 (+27.57%) Closing price 10/9/2025 03:58 PM EasternExtended Trading$0.43 +0.02 (+4.09%) As of 05:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Iterum Therapeutics NASDAQ:ITRM$0.81 +0.04 (+5.65%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$0.83 +0.02 (+2.35%) As of 05:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Matinas Biopharma NYSEAMERICAN:MTNB$1.86 -0.01 (-0.53%) Closing price 10/9/2025 04:10 PM EasternExtended Trading$1.86 +0.00 (+0.27%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
